OptimizeRx Corporation reports developments in healthcare technology for life sciences marketing, with updates centered on tools that connect pharmaceutical brands with healthcare professionals and patients. The company’s platform uses EHR-based access, omnichannel activation, the Dynamic Audience Activation Platform, and Micro-Neighborhood audiences to support HCP and direct-to-consumer engagement.
Recurring OptimizeRx news includes product and network launches, programmatic access to EHR advertising, privacy-safe identity resolution collaborations, quarterly and annual results, debt and share-repurchase actions, and board or leadership changes. Coverage also reflects the company’s focus on privacy-compliant audience targeting and campaign measurement across healthcare marketing channels.
OptimizeRx (Nasdaq: OPRX) announced an exclusive partnership with Demandbase on August 17, 2021, to enhance digital engagement in healthcare.
This collaboration creates a comprehensive account-based experience platform, integrating direct-to-physician touchpoints. OptimizeRx will utilize Demandbase's B2B suite, expanding its digital reach across U.S. healthcare systems.
The partnership aims to personalize HCP engagement using behavioral data, potentially boosting revenue as life sciences shift towards digital strategies.
OptimizeRx Corp. (Nasdaq: OPRX) reported a significant 55% increase in revenue, reaching $13.6 million for Q2 2021, compared to $8.8 million in the same quarter last year. The company closed 19 enterprise contracts, expanding its pipeline from 46 to 63. Notably, the number of brands adopting its solutions surged from 80 to 140 in six months. The gross profit margin increased slightly to 59%, and net income turned positive at $0.4 million or $0.02 per share. Cash reserves stood at $83.9 million as of June 30, 2021.
OptimizeRx Corp. (Nasdaq: OPRX) will hold a conference call on August 4, 2021, at 4:30 p.m. Eastern time to discuss its Q2 2021 results, ending June 30, 2021. Financial results will be issued ahead of the call, which will be followed by a Q&A session. The company provides digital health solutions, connecting healthcare providers and patients through its platform. This platform enhances medication adherence and creates new engagement opportunities for life science companies during the patient journey.
OptimizeRx has signed an agreement with a leading pharmaceutical company to enhance a patient affordability initiative.
The OptimizeRx platform utilizes real-world evidence (RWE) to assist physicians in managing Medicare patients’ treatment plans, preventing lapses due to coverage gaps.
This initiative aims to support patients in staying on their prescribed treatment without unexpected out-of-pocket costs, thus improving health outcomes.
OptimizeRx connects healthcare providers and patients, enhancing treatment adherence through its AI-driven platform.
OptimizeRx Corp. (Nasdaq: OPRX), a leader in digital health solutions, is strengthening its enterprise solutions in oncology, cardiology, and immunology. Customer engagement in these areas has surged by 600% in two years, now projected to represent at least 50% of future revenue. The company is enhancing partnerships and expanding its omni-channel platform, reaching over 50% of U.S. oncologists. Notably, specialty medicines account for 53% of spending, reflecting significant market growth.
Summary not available.
OptimizeRx Corp. (Nasdaq: OPRX) announced that CEO Will Febbo will participate in a fireside chat at the William Blair 41st Annual Growth Stock Conference. The event will take place virtually on June 2, 2021, from 9:20-9:50 AM CT (10:20-10:50 AM ET). A live webcast and replay will be available on the company's investor relations website. OptimizeRx offers digital health solutions connecting healthcare providers and patients, aiming to enhance medication affordability and adherence.
OptimizeRx Corp. (Nasdaq: OPRX), a leader in digital health solutions, will participate in the RBC Capital Markets Global Healthcare Virtual Conference. CEO Will Febbo is scheduled for a fireside chat on May 19, 2021, at 8:00 a.m. ET. The presentation can be accessed live on the company's investor website. OptimizeRx offers a digital platform that connects healthcare providers and patients, enhancing medication affordability and adherence through innovative communication solutions. For updates, follow OptimizeRx on social media or visit their website.
OptimizeRx Corp. (Nasdaq: OPRX) reported a 48% revenue increase in Q1 2021, reaching $11.2 million compared to $7.6 million year-over-year. Gross profit rose 41% to $6.1 million, though GAAP net loss was $0.6 million or $(0.04) per share.
The company achieved cash flow positivity from operations at $1.7 million, bolstered by a successful equity offering raising $70.7 million. 33 enterprise contracts worth $25 million in annual value were secured. Cash and cash equivalents soared to $82.3 million by March 31, 2021.
OptimizeRx Corporation (Nasdaq: OPRX) will hold a conference call on May 6, 2021, at 4:30 p.m. Eastern to discuss its first quarter financial results for the period ending March 31, 2021. A press release with the financial results will precede the call, where management will address questions afterward. Interested parties can access the call via a toll-free number or the web. The company is recognized for its digital health solutions, connecting a significant network of healthcare providers and patients to enhance medication adherence.